Adelmidrol + sodium hyaluronate in IC/BPS or conditions associated to chronic urothelial inflammation. A translational study. (August 2018)

• Record Type: Journal Article
• Authors: Ostardo, Edoardo; Impellizzeri, Daniela; Cervigni, Mauro; Porru, Daniele; Sommariva, Monica; Cordaro, Marika; Siracusa, Rosalba; Fusco, Roberta; Gugliandolo, Enrico; Crupi, Rosalia; Schievano, Carlo; Inferrera, Antonino; Di Paola, Rosanna; Cuzzocrea, Salvatore
• Is Part Of: Pharmacological research. Volume 134(2018)
• Page Start: 16
• Page End: 30
• Publication Date: 2018-08
• Subjects: CYP cyclophosphamide -- IC/BPS interstitial cystitis/painful bladder syndrome -- MCs mast cells -- iNOS nitric oxide synthase -- ZO-1 zonula occludens type 1 -- PEA palmitoylethanolamide -- MPO Myeloperoxidase -- (NF-κB) p65 nuclear factor-κB -- (IL)-1β interleukin -- MCP-1 monocyte chemoattractant protein-1 -- NGF nerve growth factor; Sodium hyaluronate (pubchem CID:3084049) -- adelmidrol (pubchem CID: 176874); IC/BPS -- Adelmidrol++ -- Sodium hyaluronate -- Urothelial inflammation -- Reactive oxygen species; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2018.05.013
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic bladder condition characterized by frequent urination, bladder inflammation and pain. It is a particular challenging disease and a clear unmet medical need in terms of identifying new therapeutic strategies. The aim of study was to evaluate the anti-inflammatory effects of intravesical Vessilen ® (a new formulation of 2% adelmidrol (the diethanolamide derivative of azelaic acid) + 0.1% sodium hyaluronate) administration in rodent models of IC/BPS and in IC/BPS patients or other bladder disorders. Acute and chronic animal models of cystitis were induced by a single or repetitive intraperitoneal injections of cyclophosphamide (CYP); patients with IC/BPS or with bladder pain syndrome associated with symptoms of the lower urinary tract treated once weekly by bladder instillation of Vessilen ® for 8 weeks. CYP instillation caused macroscopic and histological bladder alterations, inflammatory infiltrates, increased mast cell numbers, bladder pain, increased expression of nitrotyrosine, decreased expression of endothelial tight junction zonula occludens-1. Intravesical Vessilen® treatment was able to ameliorate CYP induced bladder inflammation and pain by inhibiting nuclear factor-κB pathway and inflammatory mediator levels as well as reduced mechanical allodynia and nerve growth factor levels. A significant improvement in quality of life and symptom intensity were evident in patients with IC/BPS or other bladder disorders treated with Vessilen ® . Vessilen ® could be a new therapeutic approach for human cystitis.